Search clinical trials for: Valsartan Hydrochlorothiazide

Total 831 results

Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
Novartis

Completed

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Hypertension

India
Novartis

Completed

A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension

Hypertension

United States
Sanofi

Completed

Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension (COSIMA2)

Hypertension

India, Malaysia, Philippines, Singapore, Taiwan, Tunisia, Egypt, Korea, Republic of, Hong Kong, Indonesia, Morocco, Pakistan, Thailand, Vietnam
Novartis Pharmaceuticals
Baker Heart and Diabetes Institute

Completed

Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)

Hypertension

United States, Australia
Novartis

Completed

Hypertension and Cardiovascular Risk Factors

HYPERTENSION
Yonsei University

Completed

Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

Hypertension

Korea, Republic of
Organon and Co

Completed

BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (EASE)

Hypertension
Novartis Pharmaceuticals

Completed

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (TurkuPET)

Heart Failure

Finland
Damanhour University

Completed

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses) (PKVH PART II)

Healthy Normotensive Participants
Novartis

Completed

Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone

Hypertension

Switzerland, Germany
Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
Novartis

Completed

VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil

Hypertension

Switzerland, Germany
Novartis

Completed

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

Hypertension

United States
Novartis

Completed

Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)

Hypertension
Novartis

Completed

Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months

Hypertension

Singapore
Boehringer Ingelheim

Completed

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

Hypertension

United States
Boehringer Ingelheim

Completed

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Hypertension | Diabetes Mellitus, Type 2

Taiwan, Korea, Republic of, United States, New Zealand, Australia, Argentina, Canada, Mexico
Novartis

Completed

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

METABOLIC SYNDROME | HYPERTENSION | PRE-HYPERTENSION

United States
Novartis

Completed

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

Hypertension

United States
Novartis

Completed

Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.

Hypertension

Switzerland
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

Hypertension

United States
Damanhour University

Completed

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (PKVH)

Healthy Normotensive Participants

Egypt
Radboud University Medical Center

Completed

Nijmegen Antihypertensive Management Improvement Study (NAMIS)

Primary Hypertension

Netherlands
Novartis

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide

Hypertension

Switzerland, Germany
Forest Laboratories

Completed

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Hypertension

United States
Novartis

Completed

A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy

Hypertension

Switzerland
Novartis

Completed

Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension

Hypertension

Brazil
Novartis

Completed

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Hypertension

United States, Canada, Germany, Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Hypertension

United States
Novartis

Completed

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

Hypertension

United States
Novartis

Completed

Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients

Hypertension

Taiwan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension

Resistant Hypertension

China
Hospital Israelita Albert Einstein
Libbs Farmacêutica LTDA

Recruiting

Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (OPTION TREAT)

Hypertension

Brazil
Novartis

Completed

VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women

Hypertension

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Hypertension

United States, Colombia, Spain, Germany, Taiwan, Russian Federation, Argentina, France, Italy, Korea, Republic of, Japan, Greece
Qingdao Central Hospital

Not yet recruiting

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypertension

China
TSH Biopharm Corporation Limited

Completed

ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria

Hypertension | Diabetes Mellitus, Type 2 | Albuminuria

Taiwan
Novartis

Completed

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT)

Stage 2 Systolic Hypertension

United States
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
Novartis Pharmaceuticals

Completed

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Essential Hypertension

China, Taiwan, Japan, Thailand, Korea, Republic of
Yuhan Corporation

Completed

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Cardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic Peptides

United States
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PRECISION-BP)

Cardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone System

United States
Insel Gruppe AG, University Hospital Bern

Completed

Hydrochlorothiazide for Kidney Stone Recurrence Prevention (NOSTONE)

Nephrolithiasis

Switzerland
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Hypertension

United States
Novartis

Completed

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

Hypertension

Japan
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China

3

Subscribe